• Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA decided the firm is sole first-to-file for both Orange Book patents listed for wakefulness drug Provigil (modafinil) and, therefore, Teva's abbreviated new drug application alone is entitled to 180-day exclusivity.